| 📌 The essentials On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa (IMP321, Immutep) for the treatment of soft tissue sarcoma. The designation is based on data from the Phase 2 EFTISARC-NEO trial (NCT06128863), which met its primary endpoint with a median tumor hyalinization and fibrosis of 51.5% across 38 evaluable patients, well above both the trial’s prespecified threshold of 35% and the historical benchmark of approximately 15% with radiotherapy alone. What eftilagimod alfa is: a soluble form of LAG-3 protein that activates antigen-presenting cells to stimulate a broad immune response. It is not a checkpoint inhibitor. It works through a distinct, complementary mechanism to pembrolizumab. What Orphan Drug Designation means: eligibility for 7 years of market exclusivity, tax credits for clinical development costs, fee waivers, and enhanced FDA guidance. It does not mean the drug is approved or that approval is certain. Where the program stands: Immutep is reviewing its development strategy following the discontinuation of its Phase 3 TACTI-004 trial in head and neck cancer. The company has indicated the orphan designation may guide future decisions about advancing eftilagimod alfa in soft tissue sarcoma toward a late-stage neoadjuvant trial. |
|---|
Soft tissue sarcoma is not a single disease. It is a family of more than 70 distinct histologic subtypes arising from connective tissues including fat, muscle, nerves, tendons, and blood vessels throughout the body. They are rare in aggregate, accounting for roughly 1% of adult malignancies in the United States, with approximately 13,000 new diagnoses and 5,000 deaths annually. That rarity has been part of the problem: the treatment landscape has moved slowly in comparison to more common cancers, and many subtypes have seen no meaningful new approvals in decades.
The current standard treatment for resectable soft tissue sarcoma is surgery, often with preoperative or postoperative radiation therapy. For higher-grade or larger tumors, neoadjuvant radiation before surgery is standard, but its response rate, measured by how much tumor the radiation kills before the surgeon removes it, has historically been modest. Pathologic response rates with radiotherapy alone typically produce median hyalinization and fibrosis around 15%. Chemotherapy is used in some settings but adds substantial toxicity with variable benefit.
Immunotherapy has largely failed to show meaningful activity in most sarcoma subtypes. The complex, immunosuppressive tumor microenvironment of soft tissue sarcomas has made checkpoint inhibitors less effective here than in more immunogenic tumors like melanoma or lung cancer. The EFTISARC-NEO trial is testing a different approach: rather than simply blocking inhibitory immune checkpoints, it adds a drug designed to actively stimulate the immune system’s antigen-presenting machinery at the same time.
On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma, citing the EFTISARC-NEO data as the basis for the designation. This post covers what eftilagimod alfa is, what the trial actually showed, what the designation means in practice, and where this program sits relative to the broader and slowly evolving landscape of sarcoma treatment.
What Eftilagimod Alfa Is: A LAG-3 Agonist, Not a Checkpoint Inhibitor
Eftilagimod alfa (IMP321) is a soluble, recombinant form of LAG-3 (Lymphocyte Activation Gene-3), a protein expressed on the surface of activated T cells and natural killer cells. LAG-3 is commonly discussed in the context of immune checkpoint inhibitors, and several anti-LAG-3 antibodies (including relatlimab, which is approved in combination with nivolumab in melanoma) block LAG-3 on T cells to prevent exhaustion.
Eftilagimod alfa works completely differently. Rather than blocking LAG-3 on T cells, it acts as an agonist for MHC class II molecules on antigen-presenting cells (APCs), including dendritic cells and macrophages. By binding MHC class II on APCs, it activates them to present tumor antigens more efficiently to both CD4+ and CD8+ T cells, stimulating a broad adaptive and innate immune response. The goal is to transform a cold, immunosuppressed tumor microenvironment into a hot one where the immune system can recognize and attack the cancer.
This mechanism is complementary to pembrolizumab, which works by removing the inhibitory PD-1/PD-L1 brake on T cell activity. The hypothesis behind the EFTISARC-NEO combination is that eftilagimod alfa primes the immune system by activating APCs, pembrolizumab removes the brake on T cell activity, and radiotherapy releases tumor antigens by killing cancer cells, creating a coordinated, amplified anti-tumor immune response.
| Why soft tissue sarcoma has been resistant to immunotherapy The tumor microenvironment of soft tissue sarcoma is characterized by low mutational burden in most subtypes, sparse T cell infiltration, and high levels of immunosuppressive cells including tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. This immunosuppressive landscape is why single-agent checkpoint inhibitors have shown limited activity in most sarcoma subtypes: removing the brake on T cells is less effective when there are few T cells present and an environment actively working to suppress them. Radiotherapy can partially address this by releasing tumor antigens and creating an inflammatory signal that recruits immune cells. Eftilagimod alfa is designed to amplify that immunological priming step by activating APCs to process and present those antigens more effectively. The combination hypothesis is therefore mechanistically grounded: prime with efti, release antigens with radiation, and remove the T cell brake with pembrolizumab. |
|---|
What Is Soft Tissue Sarcoma and Who Does It Affect?
Soft tissue sarcomas are cancers that arise from mesenchymal tissue, the connective tissues that form the structural framework of the body. The major histologic groups include:
- Undifferentiated pleomorphic sarcoma (UPS): Among the most common high-grade subtypes in adults. Aggressive with a high rate of local and distant recurrence.
- Liposarcoma: Arises from fat tissue. Several subtypes with varying aggressiveness, from well-differentiated (low-grade) to dedifferentiated (high-grade).
- Leiomyosarcoma: Arises from smooth muscle. Common in the uterus and retroperitoneum.
- Synovial sarcoma: Affects primarily young adults and adolescents. One of the few subtypes with a recently approved immunotherapy (afami-cel, discussed below).
- Myxofibrosarcoma: Common in the extremities of older adults. High local recurrence rate.
EFTISARC-NEO specifically enrolled patients with grade 2 or 3, stage III sarcomas of the extremities or trunk with specific eligible histologies. The study was conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, primarily funded through an approved grant from the Polish Medical Research Agency.
Most soft tissue sarcomas present as painless masses. Diagnosis typically requires core needle biopsy and centralized pathologic review at a center with sarcoma expertise, because accurate subtype identification is critical for treatment planning. Management of high-grade resectable sarcoma typically involves a multidisciplinary team including surgical oncology, radiation oncology, and medical oncology.
The EFTISARC-NEO Trial: What the Data Shows
Trial design
EFTISARC-NEO (NCT06128863) is a Phase 2, single-arm, single-center investigator-initiated study conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. It evaluates eftilagimod alfa administered concurrently with pembrolizumab (Keytruda, Merck) and standard radiotherapy as neoadjuvant treatment in patients with resectable soft tissue sarcoma.
Eligible patients were adults aged 18 or older with ECOG performance status 0 or 1, grade 2 or 3 sarcomas, and eligible histologies including undifferentiated pleomorphic sarcoma, myxofibrosarcoma, pleomorphic liposarcoma, and pleomorphic leiomyosarcoma, among others. Tumors were required to be located in the deep extremities, girdles, or superficial trunk. No adjuvant treatment was permitted after surgery, with 24 months of regular follow-up.
The treatment sequence: eftilagimod alfa and pembrolizumab administered during the 25-fraction radiotherapy course, followed by surgical resection. The primary endpoint was tumor hyalinization and fibrosis at the time of surgical resection.
The primary endpoint: what tumor hyalinization and fibrosis actually measures
Tumor hyalinization and fibrosis is a validated histopathologic endpoint in soft tissue sarcoma that quantifies the proportion of the tumor that has been replaced by scar tissue and devitalized cells after treatment, reflecting treatment-induced tumor cell kill. It is measured by a pathologist examining the surgical specimen after tumor removal. Higher hyalinization and fibrosis percentages indicate more extensive tumor destruction.
This endpoint is clinically meaningful because it has been associated with improved outcomes in multiple sarcoma studies. A higher pathologic response rate at surgery predicts better overall survival and recurrence-free survival compared to lower response rates, even though it is measured at a single timepoint. It is analogous in concept to pathologic complete response (pCR) used as a surrogate endpoint in breast cancer neoadjuvant trials.
The historical benchmark with radiotherapy alone in comparable patient populations is approximately 15% median hyalinization and fibrosis. The EFTISARC-NEO trial was designed with an ambitious prespecified threshold: the trial would be considered successful if the median exceeded 35%.
Results
| Outcome | Result | Context |
|---|---|---|
| Evaluable patients (full analysis) | 38 | Target enrollment completed January 2025 |
| Median tumor hyalinization/fibrosis | 51.5% | vs 35% prespecified target; vs ~15% historical with RT alone |
| Patients achieving 35% or greater | Majority of evaluable patients | Exceeded prespecified threshold |
| Consistency across subtypes | Yes | Benefit seen across multiple STS histologies |
| Grade 3 or higher toxicity from efti or pembrolizumab | 0 | No high-grade immune-related toxicity |
| Surgical delays related to treatment | 0 | All patients proceeded to planned surgery |
| Translational immune data | Showed immune activation consistent with mechanism of action | APC activation, CD4+ and CD8+ T cell engagement |
Source: ESMO Congress 2025 Proffered Paper presentation. CTOS 2025 Annual Meeting Oral Presentation. Immutep press release April 15, 2026.
The 51.5% median is more than a 3-fold increase over the 15% historical benchmark. The fact that no patients had their surgery delayed due to treatment toxicity is a practical clinical finding that matters in the neoadjuvant setting, where surgery timing is part of the overall treatment plan. The translational data showing immune activation consistent with the proposed mechanism of action, including evidence of APC engagement and downstream T cell responses in the tumor microenvironment, supports the mechanistic hypothesis rather than simply showing an empirical effect.
Full detailed results from the complete 38-patient analysis were presented at ESMO Congress 2025 as a Proffered Paper, a higher-tier presentation format at ESMO, and at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting.
What Orphan Drug Designation Means and What It Does Not
FDA Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. Soft tissue sarcoma meets this threshold.
The designation provides:
- 7 years of market exclusivity after approval, protecting against generic or biosimilar competition
- Tax credits covering 25% of qualified clinical trial costs
- Fee waivers for FDA application fees
- Enhanced regulatory guidance and potential for more frequent FDA interaction during development
- Eligibility for Orphan Drug grants for qualifying organizations
The European Medicines Agency had already granted a similar designation for eftilagimod alfa in soft tissue sarcoma before the FDA designation, establishing parallel orphan status on both sides of the Atlantic.
What the designation does not mean: it is not approval, not a guarantee of approval, and does not reduce the evidence standard required for approval. A drug with Orphan Drug Designation still needs to demonstrate substantial evidence of safety and efficacy in adequate and well-controlled clinical studies to be approved. The designation is a development incentive, not a regulatory shortcut.
The TACTI-004 Context: Why This Is a Pivotal Moment for Eftilagimod Alfa
Understanding the significance of the soft tissue sarcoma program requires understanding what happened in Immutep’s flagship program.
The TACTI-004 trial was a Phase 3 study evaluating eftilagimod alfa in combination with pembrolizumab for first-line treatment of head and neck squamous cell carcinoma (HNSCC), the largest and most advanced clinical program in eftilagimod alfa’s development history. In early 2026, Immutep announced the discontinuation of TACTI-004, citing the emerging competitive landscape in first-line HNSCC where multiple approved combination regimens had raised the bar for demonstrating meaningful superiority.
The discontinuation was a significant setback for the broader eftilagimod alfa program. However, the company has been careful to distinguish the HNSCC competitive context from the sarcoma setting, where there is no equivalent competitive landscape and the therapeutic need remains largely unmet.
For soft tissue sarcoma specifically, the evidence picture is different. The EFTISARC-NEO results are in a disease with no approved immunotherapy in the neoadjuvant setting, limited treatment advances in recent years, and a validated pathologic endpoint with prognostic relevance. The Orphan Drug Designation provides development incentives that could support moving toward a formal registrational trial.
The Broader Sarcoma Treatment Landscape: Where This Fits
The soft tissue sarcoma treatment landscape has seen modest but meaningful recent progress after years of relative stagnation.
The most directly relevant recent approval is afami-cel (Tecelra, Adaptimmune), the first T cell receptor-engineered cell therapy approved by the FDA, which received approval in August 2024 for unresectable or metastatic synovial sarcoma in adults and adolescents 16 or older after prior treatment. Afami-cel targets MAGE-A4, an antigen expressed on synovial sarcoma cells, and produced an overall response rate of 39% in the pivotal trial. It represents the first approved immunotherapy in soft tissue sarcoma, opening the door to immune-based approaches in a tumor type where they had previously largely failed.
Eftilagimod alfa is pursuing a different subtype of sarcoma, a different treatment setting (neoadjuvant rather than metastatic), and a different mechanism (APC activation rather than T cell receptor engineering). The two programs are not in competition; they address different clinical scenarios within the same broad disease category.
Other relevant pipeline programs in soft tissue sarcoma include olaratumab, which is being re-evaluated after its initial Phase 3 failure, and multiple combinations exploring CDK4/6 inhibitors for well-differentiated and dedifferentiated liposarcoma, which overexpresses CDK4.
What This Means for Patients and Oncologists
For patients currently being treated for resectable soft tissue sarcoma, eftilagimod alfa is investigational. It is not approved and is not available outside of clinical trials. The EFTISARC-NEO trial completed enrollment in January 2025 and is currently in the follow-up period. Immutep has indicated that the Orphan Drug Designation may support planning a late-stage neoadjuvant trial, but no registration trial has been announced or started.
For patients interested in sarcoma clinical trial options, ClinicalTrials.gov is the primary resource for identifying open enrollment studies. The Sarcoma Foundation of America and the Sarcoma Alliance maintain patient-facing resources on sarcoma subtypes, treatment options, and clinical trial access. Sarcoma care is highly specialized, and management at a National Cancer Institute-designated cancer center or a dedicated sarcoma program is strongly recommended for diagnosis and treatment planning.
For clinicians, the EFTISARC-NEO results represent the strongest prospective data for an immunotherapy-containing regimen in resectable high-grade soft tissue sarcoma to date, though the single-arm, single-center Phase 2 design limits direct actionability without confirmatory data. The translational correlates presented at ESMO 2025 and CTOS 2025 supporting the proposed mechanism of action are a meaningful addition to the evidence base.
For context on how the FDA has been using orphan drug and rare disease designations alongside other regulatory tools to accelerate rare disease drug development in 2026, see our post on the UX111 gene therapy for Sanfilippo syndrome, which holds multiple FDA rare disease designations and is currently under review, and our post on the first gene therapy for genetic deafness, which was approved under the Rare Pediatric Disease PRV program.
Sources
Immutep Orphan Drug Designation press release: Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma. GlobeNewswire. April 15, 2026.
Immutep company website: Eftilagimod Alfa Pipeline. immutep.com.
EFTISARC-NEO trial registration: NCT06128863. ClinicalTrials.gov.
Targeted Oncology ODD coverage: FDA Grants Orphan Drug Designation to Eftilagimod Alfa for Soft Tissue Sarcoma. targetedonc.com. April 2026.
OncLive primary endpoint coverage: Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma. onclive.com. May 2025.
CancerNetwork coverage: Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma. cancernetwork.com. May 2025.
Targeted Oncology Phase 2 results: EFTISARC-NEO Trial Meets Primary End Point in Soft Tissue Sarcoma. targetedonc.com. May 2025.
Afami-cel FDA approval: FDA approves afami-cel for synovial sarcoma. FDA.gov. August 2024.
FDA Orphan Drug Designation program: Orphan Drug Designations and Approvals. FDA.gov.
Orphan Drug market exclusivity and incentives: Designating an Orphan Product. FDA.gov.
LAG-3 biology reference: LAG-3 and its role in cancer immunotherapy. PMC7938019.
STS tumor microenvironment: Tumor Microenvironment in Soft Tissue Sarcoma. PMC9912345.
Hyalinization/fibrosis as prognostic endpoint: Pathologic Response in Soft Tissue Sarcoma. PMC4580342.
Soft tissue sarcoma overview: Soft Tissue Sarcoma. American Cancer Society.
Patient resources: Sarcoma Foundation of America | Sarcoma Alliance | ClinicalTrials.gov: Soft Tissue Sarcoma | NCI Sarcoma Information
| Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. Eftilagimod alfa is investigational and not currently FDA-approved for soft tissue sarcoma or any other indication in the United States. Treatment decisions for soft tissue sarcoma should be made in consultation with a qualified oncologist at a center with sarcoma expertise. |
|---|